LEGN:NASDAQ, Legend Biotech Corporation
LEGN stock overview
Legend Biotech Corporation (LEGN:NASDAQ) closed at $18.37 on October 19, 2026,
down 0.60% on the day.
The stock trades 51.0% below its 52-week high of $37.50
and 13.1% above its 52-week low of $16.24.
Over the past year, it lost 42.2%.
Legend Biotech Corporation is part of the Health Care sector.
Key figures
- Price
- $18.37
- Day change
- -0.60%
- Volume
- 346,400
- Average volume
- 2,344,206
- Market cap
- 3B+
- 52-week range
- $16.24 – $37.50
- 50-day average
- $19.71
- 200-day average
- $22.24
Performance
| 5D |
1M |
3M |
6M |
1Y |
| +3.82% |
+5.12% |
-20.38% |
-26.29% |
-42.18% |
Price action over the past year
In 252 trading sessions since October 16, 2025, LEGN closed higher on 107 days (42%).
Its best day was June 2, 2026 (+42.22%) and its worst was June 18, 2026 (-16.68%).
The stock moved 10% or more in a single session 8 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
LEGN news
-
Oct 15, 2026:
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
-
Oct 4, 2026:
Legend Biotech (LEGN) Tests Its Valuation After Fresh CARVYKTI Five Year Data
-
Oct 2, 2026:
Sector Update: Healthcare Stocks Steady Late Afternoon
-
Oct 2, 2026:
Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says
-
Oct 1, 2026:
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
-
Sep 29, 2026:
Asian Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
-
Sep 25, 2026:
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
-
Sep 25, 2026:
Can Legend Biotech (LEGN) Turn Cell Therapy Scale Into Compounding Wealth?
About Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from North America.
Similar stocks
Find more stocks like LEGN with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.